Getting your player ready...
TRENTON, N.J. — A congressional committee has broadened its probe of the delay by drugmakers Merck and Schering-Plough in releasing data about their cholesterol drug Vytorin, saying Internet postings indicate they knew the results long before releasing them.
The controversial study found Vytorin wasn’t as effective as advertised.
The House Committee on Energy and Commerce has demanded documents from the chief executives of both drugmakers, the Food and Drug Administration and the operator of and webmaster for Cafepharma Inc. On the site, postings indicate some reps knew about the study’s results as early as last March.
